Tülin Tuğlular

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Michel Attal, Paul G. Richardson, S. Vincent Rajkumar et al. · The Lancet · 2019 · 636 citations

Medicine, Hematology, Pharmacotherapy +15

Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

Meletios Α. Dimopoulos, Evangelos Terpos, Mario Boccadoro et al. · The Lancet Oncology · 2021 · 327 citations

Medicine, Hematology, Oncology +14

Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience

Hüseyin Saffet Beköz, Nuri Karadurmuş, S. Paydaş et al. · Annals of Oncology · 2017 · 69 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

MERGE: A Multinational, Multicenter Observational Registry for Myeloproliferative Neoplasms in Asia, including Middle East, Turkey, and Algeria

Mohamed A. Yassin, Alì Taher, Vikram Mathews et al. · Cancer Medicine · 2020 · 63 citations · Full text

Medicine, Hematology, Internal Medicine +17

Pesg PNH diagnosis, follow-up and treatment guidelines.

Fahri Şahin, Olga Meltem Akay, Mesut Ayer et al. · PubMed · 2016 · 49 citations · Full text

Medicine, Hematology, Urology +12